

PANLAR Consensus Recommendations for the Management in Osteoarthritis of Hand, Hip, and Knee

Oscar Rillo, MD,* Humberto Riera, MD, PhD,† Carlota Acosta, MD,‡ Verónica Liendo, MD,§
 Joyce Bolaños, MD,|| Ligia Monterola, MD,¶ Edgar Nieto, MD,# Rodolfo Arape, MD,**
 Luisa M. Franco, MD,†† Mariflor Vera, MD,‡‡ Silvia Papisidero, MD,* Rolando Espinosa, MD,||||
 Jorge A. Esquivel, MD,¶¶ Renee Souto, MD,### Cesar Rossi, MD,## José F. Molina, MD,***
 José Salas, MD,††† Francisco Ballesteros, MD,‡‡‡ Francisco Radrigan, MD,‡‡‡ Marlene Guibert, MD,§§§
 Gil Reyes, MD,§§§ Araceli Chico, MD,||||| Walter Camacho, MD,¶¶¶ Lorena Urioste, MD,####
 Abraham Garcia, MD,**** Isa Iraheta, MD,**** Carmen E. Gutierrez, MD,†††† Raúl Aragón, MD,§§§
 Margarita Duarte, MD,§§§§ Margarita Gonzalez, MD,||||||| Oswaldo Castañeda, MD,¶¶¶¶
 Juan Angulo, MD,##### Ibsen Coimbra, MD,***** Roberto Munoz-Louis, MD,†††††
 Ricardo Saenz, MD,‡‡‡‡‡‡ Carlos Vallejo, MD,§§§§§ Julio Briceño, MD,||||||| Ramón P. Acuña, MD,¶¶¶¶¶
 Anibal De León, MD,##### Anthony M. Reginato, MD, PhD,***** Ingrid Möller, MD,††††††
 Carlo V. Caballero, MD, PhD,‡‡‡‡‡‡ and Maritza Quintero, MD, PhD†

Objective: The objective of this consensus is to update the recommendations for the treatment of hand, hip, and knee osteoarthritis (OA) by agreeing on key propositions relating to the management of hand, hip, and knee OA, by identifying and critically appraising research evidence for the effectiveness of the treatments and by generating recommendations based on a combination of the available evidence and expert opinion of 18 countries of America.

Methods: Recommendations were developed by a group of 48 specialists of rheumatologists, members of other medical disciplines (orthopedics and physiatrists), and three patients, one for each location of OA. A systematic review of existing articles, meta-analyses, and guidelines for the management of hand, hip, and knee OA published between 2008 and January 2014 was undertaken. The scores for Level of Evidence and Grade of Recommendation were proposed and fully consented within the committee based on The American Heart Association Evidence-Based Scoring System. The level of agreement was established through a variation of Delphi technique.

Results: Both “strong” and “conditional” recommendations are given for management of hand, hip, and knee OA and nonpharmacological, pharmacological, and surgical modalities of treatment are presented according to the different levels of agreement.

Conclusions: These recommendations are based on the consensus of clinical experts from a wide range of disciplines taking available evidence into account while balancing the benefits and risks of nonpharmacological, pharmacological, and surgical treatment modalities, and incorporating their preferences and values. Different backgrounds in terms of patient education or drug availability in different countries were not evaluated but will be important.

Key Words: osteoarthritis of the hand, hip, and knee, consensus recommendations

(*J Clin Rheumatol* 2016;22: 345–354)

From the *Servicio de Reumatología del Hospital Ignacio Pirovano, Buenos Aires, Argentina; †Instituto Autónomo Hospital Universitario de Los Andes, Universidad de Los Andes, Mérida, Venezuela; ‡Complejo Hospitalario Universitario “Ruiz y Páez”, Ciudad Bolívar, Venezuela; §Unidad de Investigación Reumatológica, Clínica Félix Boada, Caracas, Venezuela; ||Hospital Pérez Carreño, Caracas, Venezuela; ¶Clínica Colinas, Anzoátegui, Venezuela; #Instituto Autónomo Hospital Universitario de Los Andes, Servicio de Traumatología, Universidad de Los Andes, Mérida, Venezuela; **Centro Clínico La Isabelica, Carabobo, Venezuela; ††Instituto Docente de Urología, Valencia, Venezuela; ‡‡LabMice, Universidad de Los Andes, Mérida, Venezuela; §§Departamento de Reumatología, |||Instituto Nacional de Rehabilitación, Ciudad de México, México; ¶¶Departamento de Medicina Interna, Servicio de Reumatología, Universidad Autónoma de Nuevo León, Nuevo León, México; ###Cátedra de Reumatología de la Facultad de Medicina de la Universidad de la República, Montevideo, Uruguay; ****Arthritis Clinical Research Unit at Medicare, Medellín, Colombia; †††Grupo de Reumatólogos del Caribe, Barranquilla, Colombia; ‡‡‡Departamento de Reumatología, Universidad Católica de Chile, Santiago, Chile; §§§Servicio de Reumatología, Hospital Quirúrgico 10 de Octubre, Cerro, La Habana, Cuba; ||||Servicio de Reumatología, Hospital Hermanos Ameijeiras and Servicio de Reumatología del Hospital Clínico Quirúrgico Hermanos Ameijeiras, La Habana, Cuba; ¶¶¶Servicio de Reumatología Hospital Santa Cruz, Caja Petrolera de Salud Techo Académico Universidad Católica, San Pablo, Bolivia; ####Servicio de Reumatología Kolping y Hospital Alfonso Gumucio-Techo Académico Universidad Católica, San Pablo, Bolivia; *****Post-Grado de Reumatología, AGAR, FM, UFM, Facultad de Medicina, Universidad Francisco Marroquín, Guatemala City, Guatemala; †††Servicio de Reumatología, Instituto Salvadoreño del Seguro Social, San Miguel, El Salvador; ‡‡‡Facultad de Medicina, Universidad de El Salvador, San Salvador, El Salvador; §§§Servicio de Reumatología del Hospital de Clínicas de

Asunción, Universidad Nacional de Asunción, Asunción, Paraguay; |||||Servicio de Reumatología, Hospital San Ramón, Santa Rita, Paraguay; ¶¶¶¶Universidad Peruana de Ciencias Aplicadas UPC and Servicio Reumatología, British American Hospital, Lima, Peru; #####Universidad Nacional Mayor de San Marcos, Lima, Peru; ****Departamento de Clínica Médica da Faculdade de Ciências Médicas da UNICAMP—Universidade Estadual de Campinas, São Paulo, Brazil; †††††Servicio de Reumatología, Hospital Docente Padre Billini, Clínica Abreu, Santo Domingo, Dominican Republic; ‡‡‡‡Servicio de Reumatología, Hospital Dr. Rafael A. Calderón Guardia, San José, Costa Rica; §§§§Facultad de Medicina, Pontificia Universidad Católica del Ecuador, Quito, Ecuador; |||||Unidad de Reumatología, Hospital Central de Managua, Managua, Nicaragua; ¶¶¶¶Hospital Especializado Dr. Arnulfo Arias Madrid, Panama, Panama; #####Hospital Santo Tomás, Panama, Panama; *****Division of Rheumatology, The Warren Alpert School of Medicine, Providence, RI, USA; †††††Universidad de Barcelona, Instituto Poal, Barcelona, Spain; and ‡‡‡‡†††Universidad del Norte, Barranquilla, Colombia.

The authors declare no conflict of interest.

Disclosure of funding: This study was conducted with funding from PANLAR.

Correspondence: Maritza Quintero, PhD, MD, Universidad de Los Andes, Laboratory of Rheumatic Diseases at IAHULA, Osteoarthritis Group—PANLAR (Liga Panamericana de Reumatología), Instituto Autónomo Hospital Universitario de Los Andes, Unidad de Reumatología, Facultad de Medicina, Universidad de Los Andes, Av 16 de septiembre, Mérida 5101, Venezuela. E-mail: maritzaquintero@gmail.com.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 1076-1608

DOI: 10.1097/RHU.0000000000000449

Osteoarthritis (OA) is the most common type of rheumatic disease; it is one of the main reasons for presentation to a rheumatologist. As the second most common cause of work disability after cardiovascular disease, OA incurs direct and indirect costs that have a major impact on the world economy and health systems.^{1,2}

The reported prevalence of OA ranges from 0.5 to 40% of the general population. The wide variation is attributed to the variability of the clinical features of the disease and the different criteria used for diagnosis.^{1,2} Multiple patient factors are associated with an increased risk of OA, with age being the most important, followed by gender, body mass index, and microtraumas.^{3–6} This consensus derives from a previous study of Demographic and Clinical Characteristics of 3040 Patients by the PANLAR OA study group, reporting significant differences in handling these patients and the need for reaching an agreement in the management of OA in Latin America, taking into account the conditions of this region.⁷

As there is a lack of standardized criteria for the treatment of OA, the objective of this committee of experts was to obtain agreement on OA treatment and to provide recommendations for the three most common joints affected by OA: the hand, hip, and knee.

METHODS

Literature Research

A group specialized in literature research performed a review of the literature available from 2008 to 2014 in MEDLINE, PubMed (National Center for Biotechnology Information, Bethesda, MD, USA), Cochrane Library (John Wiley & Sons, Inc., NJ, USA), and Embase (Elsevier, Madrid, Spain). The level of evidence and strength of recommendation were evaluated as shown in Table 1, which were proposed and fully consented within the committee based on The American Heart Association Evidence-Based Scoring System.⁸

A total of 896 articles were selected for analysis. The articles were classified according to the model proposed by the Center for Evidence-Based Medicine at Oxford, UK or the Jadad scale.⁹ Using these criteria, 108 articles were selected, and individual responses to questions developed through the analysis of the evidence available in the literature were given by the committee of experts.^{1–136}

Participants

Forty-eight experts in the field of OA (rheumatologists, orthopedic surgeons, and physical medicine specialties and OA

patients and a general coordinator) representing 18 Latin American countries agreed to take part in this study.

Experts' Consensus

Two sessions were conducted with the aim of reaching agreement on the final recommendations for OA in all three joints. Each participant was asked to contribute independently with questions related to key clinical aspects in the management of hand, hip, and knee OA. The consensus was reached by using a variation of the Delphi technique. The experts answered questionnaires in three rounds. After each round, a facilitator provided an anonymous summary of the experts' forecasts from the previous round and the reasons they provided for their judgments. The experts revised their earlier answers in light of the replies of other members of their panel.

Upon completion of the expert opinions, the document was edited by the Editorial Committee with the final texts approved by members of the working groups.

Recommendations for Hand OA

The recommendations for the management of hand OA are summarized in Table 2 together with the level of evidence supporting them. The treatment propositions are categorized into nonpharmacological, pharmacological, and surgical treatment modalities.

The treatment of hand OA should be individualized according to the type of OA (nodal or erosive), its location and severity, the presence of inflammation, the pain level, the level of disability and reduction in quality of life, the comorbidities and concomitant medication, and the needs and expectations of patients.^{10–15}

Nonpharmacological Treatment Modalities

Education with regard to joint protection should be provided (how to avoid adverse mechanical factors) together with an exercise regimen that includes muscle strengthening and range-of-motion exercises (IC).^{14–17} Furthermore, the combination of an orthosis (splint) with an exercise regimen to improve pain and functionality in the short and long term and an exercise regimen has been shown to decrease pain and increase the range of motion and strength in hand OA.^{10,14,16–26}

Pharmacological Treatment Modalities

Pharmacological modalities of treatment include the use of topical NSAIDs, acetaminophen/paracetamol, and oral NSAIDs. Topical NSAIDs are indicated as being effective and safe for mild to moderate pain, and they are also indicated in elderly patients

TABLE 1. Level of Evidence

Level	Meaning
A	Information from various randomized clinical trials or meta-analyses.
B	Information from a randomized clinical trial or nonrandomized studies.
C	Experts' consensus, case studies, or care standards.
Strength of Recommendation	
Level	Meaning
I	There is evidence and/or general agreement that a procedure or treatment is beneficial, useful, or effective.
II	Conflicting evidence and/or differing opinions about the efficacy of a procedure or treatment.
Ia	Evidence and/or agreement favor usefulness or efficacy.
Ib	Usefulness or efficacy is not established by evidence or opinion.
III	Conditions for which there is evidence, general agreement, or both that the procedure treatment is not useful/effective and in some cases may be harmful.

TABLE 2. Recommendations and Level of Evidence Relating to Hand OA

Proposition	Level of Evidence
Nonpharmacological treatment modalities	
1. Education with regard to joint protection together with an exercise regimen including muscle strengthening and range of motion exercises. ^{14–17}	(IC)
2. The combination of an orthosis (splint) with an exercise regimen to improve pain and functionality in the short and long term. ^{7,14,16–26}	(IIaB)
Pharmacological treatment modalities	
3. Topical NSAIDs are indicated as being effective and safe for mild to moderate pain in patients with few affected joints and in elderly patients with mild to moderate persistent pain. ^{13,30–34}	(IA)
4. Acetaminophen/paracetamol (up to 3 g/day) is the preferred oral analgesic for the long-term treatment particularly in elderly patients because of its relative safety in comparison with NSAIDs. ^{31,32}	(IB)
5. Oral NSAIDs are recommended at the lowest effective dose and for the shortest time possible if patients present inadequate response to acetaminophen/paracetamol. ^{13,31,35–37} The high risk associated with gastrointestinal and cardiovascular events should be considered.	(IA)
6. The use of chondroitin sulfate for pain relief and function is recommended as it has a good safety profile. ^{38–40}	(IA)
7. Glucosamine and chondroitin sulfate are supported in the treatment of hand and knee OA. ³⁹	(IB)
8. Steroids or intra-articular hyaluronic acid may be considered for use in the treatment of OA of the symptomatic TMC joint. ^{28,29,41}	(IIaB)
9. Intramuscular steroid is not recommended for patients with symptomatic hand OA. ⁴⁸	(IIIC)
10. The use of diacerein is not recommended as its effectiveness and the risk/benefits profile has not been established.	(IIIC)
11. Adalimumab or infliximab are not recommended in patients with secondary or erosive hand. ^{29,50,51,53}	(IIIB)
12. Bisphosphonates (clodronate) is not recommended. ⁵⁴	(IIIB)
13. Hydroxychloroquine is not recommended for the symptomatic treatment of erosive hand OA. ⁵²	(IIIC)
Surgical treatment modalities	
14. Trapeziectomy, arthroplasty with ligament reconstruction and tendon interposition, or arthrodesis may be considered for severe OA of the base of the first finger (rhizarthrosis) if severe pain and/or disability and after conservative treatment have failed. ^{53–60}	(IIbB)
15. Ligament reconstruction is recommended for stage I. Hemitrapeziectomy, TM joint arthrodesis, implant, or arthroplasty is recommended for stages II and III. Complete removal of the trapezium with or without ligament reconstruction is recommended for stage IV. ^{59,60,62}	(IIbB)

with mild to moderate persistent pain. For long-term treatment of hand OA, acetaminophen/paracetamol is the preferred oral analgesic. Other treatments in hand OA include the use of chondroitin sulfate for pain relief and function and the use of glucosamine and chondroitin sulfate. Furthermore, the use of steroids or intra-articular hyaluronic acid may be considered for use in the treatment of OA of the symptomatic TMC joint.^{28,29,41}

Surgical Treatment Modalities

Surgery (trapeziectomy, arthroplasty with ligament reconstruction and tendon interposition, or arthrodesis) may be considered for severe OA of the base of the first finger (rhizarthrosis) in patients who have severe pain and/or disability and after conservative treatment has failed (IIbB).^{53–60} Proper use of arthroplasty or arthrodesis for the affected joints requires careful consideration of the needs of the patient with regard to the affected fingers.^{55–60}

Recommendations for Hip OA

The recommendations for the management of hip OA are summarized in Table 3 together with the level of evidence supporting them. The treatment propositions are categorized into nonpharmacological, pharmacological, and surgical treatment modalities.

Nonpharmacological Treatment Modalities

Early rehabilitation is indicated to maintain mobility and prevent impairment of the extension and abduction function of the hip. Patients with hip OA should receive information and education regarding the therapeutic objectives and the importance of

changes in lifestyle, which include an exercise regimen, weight reduction, the use of walking aids (walking stick and crutches) and shoe adjustments, and other measures to prevent the progression of joint damage.^{62–64}

Available treatment options for pain relief in patients with hip OA include thermotherapy and transcutaneous electrical nerve stimulation (TENS).

Pharmacological Treatment Modalities

The use of acetaminophen/paracetamol is recommended for use in hip OA owing to its safety profile.⁶⁵ NSAIDs may be indicated at higher than usual doses to treat more severe pain.^{61,66,67} The use of hyaluronic acid in the treatment of hip OA may be beneficial and, thus, could help to reduce NSAID use.⁷⁰ In patients who suffer painful relapses and who do not respond to analgesics and NSAIDs, intra-articular corticosteroid injection (ultrasound-guided) may be beneficial to provide fast pain relief (IIaB).^{69,70}

Surgical Treatment Modalities

The recommendations for the surgical treatment of hip OA are based on the available literature from the last 2 years.

Total hip arthroplasty is a surgical modality that is undergoing continuous development. It is indicated in patients who have OA accompanied by pain and difficulty walking and whose quality of life is impaired as it improves not only these factors but also patient survival.⁷⁶ A variety of models and metal implants are available, and different approaches can be chosen such as the use of a cemented, uncemented, or hybrid prosthesis. The available evidence shows that cemented prostheses are as effective as uncemented,

TABLE 3. Recommendations and Level of Evidence Relating to Hip OA

Proposition	Level of Evidence
Nonpharmacological treatment modalities	
1. Information and education regarding the therapeutic objectives and the importance of changes in lifestyle, which include an exercise regimen, weight reduction, use of walking aids (walking stick and crutches) and shoe adjustments and other measures to prevent the progression of joint damage. ⁶²	(IB)
2. Strengthening the extensors and abductors improves functionality and can be used to prepare the patient before a hip implant. ^{61,62,64}	(IB)
3. The use of orthoses is recommended to prevent the progression of degenerative changes and improve hip function. ^{61,62,64}	(IIbB)
4. Thermotherapy can be performed to relieve pain. ^{61,62,64}	(IB)
5. Transcutaneous electrical nerve stimulation (TENS) should also be used for pain relief and to reduce stiffness. ⁶²	(IIbB)
6. Aerobic exercise performed on a regular basis and muscle stretching and strengthening and joint mobility exercises are recommended. ⁶²	(IB)
7. The use of a walking stick in the contralateral hand is also recommended. The handle should be at the level of the greater trochanter of the femur. ⁶²	(IIbB)
8. A neuromuscular bandage may be beneficial as it aids analgesia, stimulates circulation, and reduces pressure. Consequently, the patient's posture is improved. ⁶¹	(IIaB)
Pharmacological treatment modalities	
9. The use of acetaminophen/paracetamol is recommended in mild to moderate pain, owing to its safety profile. ⁶³	(IB)
10. NSAIDs (ibuprofen, naproxen, diclofenac, meloxicam) or selective COX-2 inhibitors (celecoxib, etoricoxib) may be indicated higher than usual doses in more severe pain. ^{61,66,67}	(IB)
11. Naproxen could be used in patients with cardiovascular risk. It should be administered in conjunction with a proton-pump inhibitor owing to the high gastrointestinal risk. ⁶⁶	(IA)
12. Weak opioids such as tramadol may be beneficial if there is no response to NSAIDs or COX-2 inhibitors, no toleration, or are contraindicated. ⁶¹	(IIbB)
13. The use of hyaluronic acid may be beneficial and, thus, could help to reduce the NSAID use. ⁶⁸	(IIbB)
14. Intra-articular corticosteroid injection (ultrasound-guided) may be beneficial to provide fast pain relief in patients who suffer painful relapses and who do not respond to analgesics and NSAIDs. ^{69,70}	(IIaB)
15. Avocado and soybean unsaponifiable may play a useful role, and recent studies have provided the evidence that they may slow the progression of OA. ⁷¹	(IIA)
16. The use of diacerein has reported a high rate of adverse effects, such as diarrhea and risk of liver damage. ^{49,70}	(IIIB)
Surgical treatment modalities	
17. Total hip arthroplasty is indicated when OA is accompanied by pain and walking difficulty and when the quality of life is impaired. It improves not only these factors but also patient survival. ⁷⁴ A variety of models and metal implants are available and different approaches can be chosen such as the use of a cemented, uncemented, or hybrid prosthesis.	(IA)

especially in the stem (femoral component), whereas uncemented prostheses are more effective for the cup (acetabular component).

Recommendations for Knee OA

The recommendations for the management of knee OA are summarized in Table 4 together with the level of evidence supporting them. The treatment propositions are categorized into nonpharmacological, pharmacological, and surgical treatment modalities.

Nonpharmacological Treatment Modalities

Information and education regarding treatment goals and the importance of lifestyle changes to reduce the degenerative damage of the knee joint should be provided to the patient. Use of support devices such as insoles and knee braces may help to reduce pain and stiffness.^{61,81}

Pharmacological Treatment Modalities

A wide range of pharmacological treatment modalities is available for patients with knee OA, including acetaminophen/paracetamol, oral and topical NSAIDs, and tramadol. Furthermore, oral administration of hyaluronic acid may have a beneficial therapeutic effect in patients with symptomatic knee OA and may

possibly have an even greater effect in relatively young patients.⁸² Treatment with chondroitin sulfate, which has a high safety profile, has been shown to have a beneficial effect on symptoms in patients with knee OA. In addition, it has been proven that this effect persists for 3 months after stopping the treatment (carryover effect). Recent studies have provided evidence that chondroitin sulfate use may delay OA progression.^{39,83–85} Moreover, the combined use of glucosamine and chondroitin sulfate is indicated in patients with knee OA and moderate to severe pain.^{98–100} Many other pharmacological treatment modalities are described in Table 4 (available only online only at...).

Surgical Treatment Modalities

Total knee arthroplasty may be indicated in the treatment of knee OA owing to its outstanding effect on pain and stiffness and the improvement obtained in physical activity 6 months after intervention.^{129,130} In patients with a partial rupture of the meniscus, a partial meniscectomy performed arthroscopically may be beneficial, followed by a physical therapy program.^{131,132}

DISCUSSION

From the results of a recently published study⁷ of the PANLAR OA group, we found it important to have a consensus

TABLE 4. Recommendations and Level of Evidence Relating to Knee OA

Proposition	Level of Evidence
Nonpharmacological treatment modalities	
1. Information and education regarding treatment goals and the importance of lifestyle changes to reduce the degenerative damage of the knee joint should be provided. ^{61,79}	(IA)
2. Hydrotherapy in a therapeutic tank may be indicated in mild knee pain without swelling or stiffness; it is especially beneficial for elderly patients. ⁶⁸ A program of exercises for flexibility, mobilization, and stretching can be included. ⁷⁹	(IIaA)
3. Mechanotherapy, including flexibility programs and mobilization and stretching exercises, can reduce pain and improve the range of motion of the knee. ⁷⁹	(IIbA)
4. Thermotherapy (heat and cold) may help to improve the symptoms of knee OA. ⁷⁹	(IIaA)
5. The use heat to reduce pain and stiffness before performing flexion exercises in moderate and persistent pain is recommended. ⁸¹	(IB)
6. A program of flexibility, stretching, and strengthening exercises for symptomatic knee OA is recommended as this reduces pain during walking and climbing stairs and improves the strength of the quadriceps femoris. ⁸³	(IA)
7. A daily walk is recommended as this improves muscle strength, aerobic capacity, and endurance; facilitates a good night's sleep; and reduces knee pain. ⁸¹	(IA)
8. Aerobic exercise can be implemented gradually and progressively according to each patient's level of fitness at a frequency of three or more times per week, with a minimum duration of 20 to 30 minutes per session. ⁸¹	(IA)
9. Exercises for concentric contraction of the flexor and extensor muscles of the knee are indicated as these have been shown to reduce pain both at rest and during activity. ⁸²	(IA)
10. Support devices may be useful for reducing pain and stiffness and improving the functionality of the knee. ⁷⁹ Insoles and knee braces have been shown to decrease valgus or varus and knee pain.	(IIaA)
11. The use of bandage tape may help to reduce pain in patients with joint instability knee OA. ⁸¹	(IIaB)
12. The use of assistive devices such as a walking stick, walker, or crutches is suggested as a preventive measure. A walking stick must be used in the contralateral hand and the height must be adjusted to the level of the greater trochanter, with the elbow bent at an angle of 25 to 30 degrees. ⁷⁹	(IIaB)
Pharmacological treatment modalities	
13. Acetaminophen/paracetamol is recommended at a dose of up to 3 g/day for the treatment of mild pain resulting from knee OA. Moderate gastrolesive effects may occur and patients should be monitored for possible hepatic complications. ^{63,88}	(IB)
14. NSAIDs such as diclofenac, ibuprofen, and naproxen, and selective NSAIDs including celecoxib and etoricoxib are indicated in moderate pain. ^{89,90} In all cases, gastric protection, such as a proton-pump inhibitor, is required ⁹¹ and naproxen is recommended in patients with cardiovascular risk. ⁹²	(IA)
15. Topical NSAIDs may be indicated in patients with gastrointestinal risk, even though the analgesic response decreases after 1 year of use. ⁹³⁻⁹⁵	(IA)
16. The use of tramadol in the case of severe pain in its various administration forms is recommended. ¹¹⁵	(IA)
17. Capsaicin gel was shown to be an effective treatment for knee OA accompanied by mild to moderate pain. ⁹⁶	(IIB)
18. Intra-articular corticosteroid injection (ultrasound-guided) may be beneficial to provide fast pain relief. ^{69,70}	(IIaB)
19. Chondroitin sulfate has shown to have a beneficial effect on symptoms in patients with knee OA and a high safety profile. It has been proven that its effect persists for 3 months after stopping the treatment (carryover effect). Recent studies have provided evidence that chondroitin sulfate use may delay OA progression. ^{39,83-87}	(IA)
20. The combined use of glucosamine and chondroitin sulfate is indicated in patients with knee OA and moderate to severe pain. ⁹⁷⁻¹⁰⁰	(IA)
21. Glucosamine may be beneficial for pain relief and for improving joint function in patients. ¹⁰³	(IA)
22. Avocado soybean unsaponifiable may help to slow the progression of joint damage associated with knee OA. ⁷¹	(IIbA)
23. The administration of intra-articular steroids may be reasonable for knee OA accompanied by inflammation. ¹⁰²	(IIbB)
24. Intra-articular injection of hyaluronic acid of different molecular weights has proven to be beneficial in the treatment of knee OA. ^{103,104}	(IIaB)
25. Oral administration of hyaluronic acid may have a beneficial therapeutic effect in patients with symptomatic knee OA and may possibly have an even greater effect in relatively young patients. ⁸²	(IIbC)
26. The use of strontium ranelate may be beneficial for the treatment of knee pain. ¹⁰⁵⁻¹⁰⁷	(IIbB)
27. Duloxetine may be helpful for knee OA accompanied by chronic pain. ^{108,109}	(IIbC)
28. The administration of low-dose oral steroids for a maximum of 12 weeks could be considered in patients older than 65 years. ¹¹⁰	(IIbC)
29. Intra-articular injection of platelet-rich plasma may help to relieve pain associated with knee OA ¹¹¹⁻¹¹⁷ ; however, our recommendation is to conduct better quality studies.	(IIbC)
30. The use of a supplement containing omega-3 and omega-6 fatty acids, zinc and vitamin E could be considered to reduce pain and stiffness and improve joint function, and also to reduce the intake of NSAIDs/analgesics. ¹²⁴	(IIbB)

Continued next page

TABLE 4. (Continued)

Proposition	Level of Evidence
31. Intra-articular injection of mesenchymal stem cells derived from the infrapatellar fat pad may be effective at reducing pain and improving knee function. ¹²⁸	(IIC)
Surgical treatment modalities	
32. There is no benefit associated with the use of arthroscopy in the treatment of knee OA, even in the presence of a partial meniscal tear. ¹³³	(IIIA)
33. In patients with a partial rupture of the meniscus, a partial meniscectomy performed arthroscopically may be beneficial, followed by a physical therapy program. ^{131,132}	(IIaB)
34. Total knee arthroplasty may be indicated owing to its outstanding effect on pain and stiffness and the improvement obtained in physical activity 6 months after intervention. ^{128,129} Proper preoperative planning is essential so that deformities (varus or valgus) and long-term instabilities may be corrected.	(IIaB)

on the treatment of hand, hip, and knee OA that could fit the needs of patients and specialists in America because of the significant differences in handling these patients. Moreover, the need to ensure proper care with the least economic impact, in a region in which many countries have large gaps in financial resources, and there is an important clinical diversity and various educational and cultural levels, suggests specific adaptation to regional characteristics. These recommendations for the management of patients with hand, hip, and knee OA are based on the best available evidence of benefit, safety, and tolerability of nonpharmacologic and pharmacologic and surgical treatment modalities and the consensus judgment of clinical experts from a wide range of disciplines balancing the benefits and harms of these treatments and incorporating their preferences and values.

Differences With Regard to ACR, OARS, and EULAR

Although there are other consensus and guidelines^{13,61,62,79} on the treatment of OA in the mentioned locations, this consensus focused on updating the information of the available modalities with the participation of the OA specialist and patients of 18 countries of America.

CONCLUSIONS

These recommendations are based on the consensus opinions of clinical experts from a wide range of disciplines taking available evidence into account while balancing the benefits and risks of nonpharmacological, pharmacological, and surgical treatment modalities, and incorporating their preferences and values. It is hoped that these recommendations will be utilized by healthcare providers involved in the management of patients with hand, hip, and knee OA.

The pharmacological management of OA has traditionally been centered on analgesics and NSAIDs; however, increasing toxicity warnings have been issued recently for paracetamol, traditional NSAIDs, and COX-2 inhibitors, making OA chronic treatment even more challenging. The value and therapeutic efficacy of these agents are unquestionable, but there is growing awareness that they should be used for short time periods and for specific flares of the disease. The use of safer alternatives suitable for long-term administration, such as chondroitin and glucosamine, is advisable and presents growing evidence of efficacy and safety, making them a suitable alternative for long-term control of the disease. On the other hand, the use of nonpharmacological treatments should also be taken into account due to the improvements that these may produce to the quality of life of the patient. Latin America is formed by different countries with background not similar to the European or North American countries in terms of patient education or drug

availability. How conditions in different regions of Latin America will need consideration.

ACKNOWLEDGMENT

The authors thank Dr. Luis Espinoza, Dr. Antonio Jimenez, Dr. John Reveille, Dr. Carlos Pineda (PANLAR ex-presidents), and Dr. Joan Von Feldt. The authors also thank Ximena Sanchez and Rosa Sciortino for technical support.

REFERENCES

- Pereira D, Peleteiro B, Araújo J, et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. *Osteoarthritis Cartilage*. 2011;19:1270–1285.
- Grotle M, Hagen KB, Natvig B, et al. Prevalence and burden of osteoarthritis: results from a population survey in Norway. *J Rheumatol*. 2008;35:677–684.
- Forestier R, Francon A, Briole V, et al. Prevalence of generalized osteoarthritis in a population with knee osteoarthritis. *Joint Bone Spine*. 2011;78:275–278.
- Blagojevic M, Jinks C, Jeffery A, et al. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. *Osteoarthritis Cartilage*. 2010;18:24–33.
- Martin KR, Kuh D, Harris TB, et al. Body mass index, occupational activity, and leisure-time physical activity: an exploration of risk factors and modifiers for knee osteoarthritis in the 1946 British birth cohort. *BMC Musculoskelet Disord*. 2013;14:219.
- Grotle M, Hagen KB, Natvig B, et al. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. *BMC Musculoskelet Disord*. 2008;9:132.
- Reginato AM, Riera H, Vera M, et al. Osteoarthritis in Latin America: study of demographic and clinical characteristics in 3040 patients. *J Clin Rheumatol*. 2015;21:391–397.
- Silber S. A new and rapid scoring system to assess the scientific evidence from clinical trials. *J Interv Cardiol*. 2006;19:485–92.
- Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials*. 1996;17:1–12. doi:10.1016/0197-2456(95)00134-4. PMID 8721797.
- Moe RH, Kjekken I, Uhlig T, et al. There is inadequate evidence to determine the effectiveness of nonpharmacological and nonsurgical interventions for hand osteoarthritis: an overview of high-quality systematic reviews. *Phys Ther*. 2009;89:1363–1370.
- Hagen KB, Smedslund G, Moe RH, et al. The evidence for non-pharmacological therapy of hand and hip OA. *Nat Rev Rheumatol*. 2009;5:517–519.

12. Mahendira D, Towheed TE. Systematic review of non-surgical therapies for osteoarthritis of the hand: an update. *Osteoarthritis Cartilage*. 2009;17:1263–1268.
13. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)*. 2012;64:465–474.
14. Beasley J. Osteoarthritis and rheumatoid arthritis: conservative therapeutic management. *J Hand Ther*. 2012;25:163–171; quiz 172.
15. Wenham CY, Conaghan PG. Optimizing pain control in osteoarthritis. *Practitioner*. 2010;254:23–6, 2–3.
16. Valdes K, Marik T. A systematic review of conservative interventions for osteoarthritis of the hand. *J Hand Ther*. 2010;23:334–50; quiz 351.
17. Rannou F, Poiraudou S. Non-pharmacological approaches for the treatment of osteoarthritis. *Best Pract Res Clin Rheumatol*. 2010;24:93–106.
18. Kjekens I, Smedslund G, Moe RH, et al. Systematic review of design and effects of splints and exercise programs in hand osteoarthritis. *Arthritis Care Res (Hoboken)*. 2011;63:834–848.
19. Ye L, Kalichman L, Spittle A, et al. Effects of rehabilitative interventions on pain, function and physical impairments in people with hand osteoarthritis: a systematic review. *Arthritis Res Ther*. 2011;13:R28.
20. Kjekens I. Occupational therapy-based and evidence-supported recommendations for assessment and exercises in hand osteoarthritis. *Scand J Occup Ther*. 2011;18:265–281.
21. Myrer JW, Johnson AW, Mitchell UH, et al. Topical analgesic added to paraffin enhances paraffin bath treatment of individuals with hand osteoarthritis. *Disabil Rehabil*. 2011;33:467–474.
22. Gomes Carreira AC, Jones A, Natour J. Assessment of the effectiveness of a functional splint for osteoarthritis of the trapeziometacarpal joint on the dominant hand: a randomized controlled study. *J Rehabil Med*. 2010;42:469–474.
23. Ikeda M, Ishii T, Kobayashi Y, et al. Custom-made splint treatment for osteoarthritis of the distal interphalangeal joints. *J Hand Surg Am*. 2010;35:589–593.
24. Rannou F, Dimet J, Boutron I, et al. Splint for base-of-thumb osteoarthritis: a randomized trial. *Ann Intern Med*. 2009;150:661–669.
25. Boustedt C, Nordenskiöld U, Lundgren Nilsson A. Effects of a hand-joint protection programme with an addition of splinting and exercise: one year follow-up. *Clin Rheumatol*. 2009;28:793–799.
26. Rogers MW, Wilder FV. Exercise and hand osteoarthritis symptomatology: a controlled crossover trial. *J Hand Ther*. 2009;22:10–17; discussion 19–20; quiz 18.
27. Espinosa MA, C. Cajigas JC, Esquivel JA. Reunión multidisciplinaria de expertos en diagnóstico y tratamiento de pacientes con osteoartritis. Actualización basada en evidencias. *Med Int Mex*. 2013;29:67–92.
28. Swindells MG, Logan AJ, Armstrong DJ, et al. The benefit of radiologically-guided steroid injections for trapeziometacarpal osteoarthritis. *Ann R Coll Surg Engl*. 2010;92:680–684.
29. Fioravanti A, Fabbroni M, Cerase A, et al. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. *Rheumatol Int*. 2009;29:961–965.
30. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev*. 2012:CD007400.
31. Marks JL, van der Heijde DM, Colebatch AN, et al. Pain pharmacotherapy in patients with inflammatory arthritis and concurrent cardiovascular or renal disease: a Cochrane systematic review. *J Rheumatol Suppl*. 2012;90:81–84.
32. Stukstette M, Hoogbeem T, de Ruiter R, et al. A multidisciplinary and multidimensional intervention for patients with hand osteoarthritis. *Clin Rehabil*. 2012;26:99–110.
33. Altman RD. New guidelines for topical NSAIDs in the osteoarthritis treatment paradigm. *Curr Med Res Opin*. 2010;26:2871–2876.
34. Barthel HR, Axford-Gatley RA. Topical nonsteroidal anti-inflammatory drugs for osteoarthritis. *Postgrad Med*. 2010;122:98–106.
35. Altman RD. Pharmacological therapies for osteoarthritis of the hand: a review of the evidence. *Drugs Aging*. 2010;27:729–745.
36. Altman RD. Early management of osteoarthritis. *Am J Manag Care*. 2010; (16 Suppl Management):S41–S47.
37. Spies-Dorgelo MN, van der Windt DA, Prins AP, et al. Diagnosis and management of patients with hand and wrist problems in general practice. *Eur J Gen Pract*. 2009;15:84–94.
38. Gabay C, Medinger-Sadowski C, Gascon D, et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. *Arthritis Rheum*. 2011;63:3383–3391.
39. Monfort J, Martel-Pelletier J, Pelletier JP. Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses. *Curr Med Res Opin*. 2008;24:1303–1308.
40. Moran SL, Duymaz A, Karabekmez FE. The efficacy of hyaluronic acid in the treatment of osteoarthritis of the trapeziometacarpal joint. *J Hand Surg Am*. 2009;34:942–944.
41. Shin EK, Osterman AL. Treatment of thumb metacarpophalangeal and interphalangeal joint arthritis. *Hand Clin*. 2008;24:239–250.
42. Smith AS, Dore CJ, Dennis L, et al. A randomised controlled trial of subcutaneous sodium salicylate therapy for osteoarthritis of the thumb. *Postgrad Med J*. 2010;86:341–345.
43. Mandl LA, Hotchkiss RN, Adler RS, et al. Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial. *Curr Med Res Opin*. 2009;25:2103–2108.
44. Salini V, De Amicis D, Abate M, et al. Ultrasound-guided hyaluronic acid injection in carpometacarpal osteoarthritis: short-term results. *Int J Immunopathol Pharmacol*. 2009;22:455–460.
45. Bahadir C, Onal B, Dayan VY, et al. Comparison of therapeutic effects of sodium hyaluronate and corticosteroid injections on trapeziometacarpal joint osteoarthritis. *Clin Rheumatol*. 2009;28:529–533.
46. Ingegnoli F, Soldi A, Meroni PL. Power Doppler sonography and clinical monitoring for hyaluronic acid treatment of rhizarthrosis: a pilot study. *J Hand Microsurg*. 2011;3:51–54.
47. Keen HI, Wakefield RJ, Hensor EM, et al. Response of symptoms and synovitis to intra-muscular methylprednisolone in osteoarthritis of the hand: an ultrasonographic study. *Rheumatology (Oxford)*. 2010;49:1093–1100.
48. Maarse W, Watts AC, Bain GI. Medium-term outcome following intra-articular corticosteroid injection in first CMC joint arthritis using fluoroscopy. *Hand Surg*. 2009;14:99–104.
49. Bartels EM, Bliddal H, Schöndorff PK, et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. *Osteoarthritis Cartilage*. 2010;18:289–296.
50. Güler-Yüksel M, Allaart CF, Watt I, et al. Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. *Osteoarthritis Cartilage*. 2010;18:1256–1262.
51. Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: hopes and disappointments. *Nat Rev Rheumatol*. 2013;9:400–410.
52. Saviola G, Abdi-Ali L, Campostrini L, et al. Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study. *Mod Rheumatol*. 2012;22:256–263.
53. Kozlow JH, Chung KC. Current concepts in the surgical management of rheumatoid and osteoarthritic hands and wrists. *Hand Clin*. 2011;27:31–41.

54. Diao E, Rosenwasser MP, Glickel SZ, et al. Arthritis of the thumb basal joint: old and new treatments for a common condition. *Instr Course Lect*. 2009;58:551–559.
55. Wajon A, Carr E, Edmunds I, et al. Surgery for thumb (trapeziometacarpal joint) osteoarthritis. *Cochrane Database Syst Rev*. 2009;CD004631.
56. Pritchett JW, Habryl LS. A promising thumb basal joint hemiarthroplasty for treatment of trapeziometacarpal osteoarthritis. *Clin Orthop Relat Res*. 2012;470:2756–2763.
57. Pardini AG Jr, Freitas AD, Chaves AB, et al. Comparative study between trapezium resection and tendon interposition with and without ligamentoplasty in the management of carpometacarpal arthrosis of the thumb. *J Hand Microsurg*. 2009;1:7–11.
58. Kapoutsis DV, Dardas A, Day CS. Carpometacarpal and scaphotrapeziotrapezoid arthritis: arthroscopy, arthroplasty, and arthrodesis. *J Hand Surg Am*. 2011;36:354–366.
59. Abzug JM, Osterman AL. Arthroscopic hemiresection for stage II–III trapeziometacarpal osteoarthritis. *Hand Clin*. 2011;27:347–354.
60. Forthman CL. Management of advanced trapeziometacarpal arthrosis. *J Hand Surg Am*. 2009;34:331–334.
61. Fernandes L, Hagen KB, Bijlsma JW, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. *Ann Rheum Dis*. 2013;72:1125–1135.
62. Hawkeswood JR. Evidence-based guidelines for the nonpharmacological treatment of osteoarthritis of the hip and knee. *BCM J*. 2010;52:399–403.
63. Verkleij SP, Luijsterburg PA, Bohnen AM, et al. NSAIDs vs acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity influencing the outcomes. *Osteoarthritis Cartilage*. 2011;19:921–929.
64. Beswick AD, Wyld V, Goberman-Hill R, et al. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. *BMJ Open*. 2012;2:e000435.
65. Ethgen O, Bruyere O, Richy F, et al. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. *J Bone Joint Surg Am*. 2004;86-A:963–974.
66. Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. *Ann Rheum Dis*. 2011;70:818–822.
67. Lanas A, Garcia-Tell G, Armada B, et al. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. *BMC Med*. 2011;9:38.
68. Abdulla A, Adams N, Bone M, et al. Guidance on the management of pain in older people. *Age Ageing*. 2013;42(Suppl 1):i1–57.
69. Lambert RG, Hutchings EJ, Grace MG, et al. Steroid injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2007;56:2278–2287.
70. Micu MC, Bogdan GD, Fodor D. Steroid injection for hip osteoarthritis: efficacy under ultrasound guidance. *Rheumatology (Oxford)*. 2010;49:1490–1494.
71. Christensen R, Bartels EM, Astrup A, et al. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. *Osteoarthritis Cartilage*. 2008;16:399–408.
72. Hand L. PRAC Recommends Suspending Drugs With Diacerein [Medscape Web site]. Available at: <http://www.medscape.com/viewarticle/814067>. Accessed July 15, 2015.
73. Lynch TS, Terry MA, Bedi A, et al. Hip arthroscopic surgery: patient evaluation, current indications, and outcomes. *Am J Sports Med*. 2013;41:1174–1189.
74. Dieppe P, Judge A, Williams S, et al. Variations in the pre-operative status of patients coming to primary hip replacement for osteoarthritis in European orthopaedic centres. *BMC Musculoskelet Disord*. 2009;10:19.
75. Shan L, Shan B, Graham D, et al. Total hip replacement: a systematic review and meta-analysis on mid-term quality of life. *Osteoarthritis Cartilage*. 2014;22:389–406.
76. McHugh GA, Campbell M, Luker KA. Predictors of outcomes of recovery following total hip replacement surgery: a prospective study. *Bone Joint Res*. 2013;2:248–254.
77. Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. *Open Rheumatol J*. 2013;7:119–124.
78. Hailer NP, Garellick G, Kärrholm J. Uncemented and cemented primary total hip arthroplasty in the Swedish Hip Arthroplasty Register. *Acta Orthop*. 2010;81:34–41.
79. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage*. 2014;22:363–388.
80. Fary RE, Carroll GJ, Briffa TG, et al. The effectiveness of pulsed electrical stimulation in the management of osteoarthritis of the knee: results of a double-blind, randomized, placebo-controlled, repeated-measures trial. *Arthritis Rheum*. 2011;63:1333–1342.
81. Brosseau L, Wells GA, Kenny GP, et al. The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis (OA): a knowledge translation (KT) randomized controlled trial (RCT): Part I: The Uptake of the Ottawa Panel clinical practice guidelines (CPGs). *BMC Public Health*. 2012;12:871.
82. Tashiro T, Seino S, Sato T, et al. Oral administration of polymer hyaluronic acid alleviates symptoms of knee osteoarthritis: a double-blind, placebo-controlled study over a 12-month period. *ScientificWorldJournal*. 2012;2012:167928.
83. Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. *Ann Rheum Dis*. 2011;70:982–989.
84. Möller I, Pérez M, Monfort J, et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. *Osteoarthritis Cartilage*. 2010;18(Suppl 1):S32–S40.
85. Hochberg MC, Zhan M, Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. *Curr Med Res Opin*. 2008;24:3029–3035.
86. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2009;60:524–533.
87. Zegels B, Crozes P, Uebelhart D, et al. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. *Osteoarthritis Cartilage*. 2013;21:22–27.
88. Schnitzer TJ, Tesser JR, Cooper KM, et al. A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis. *Osteoarthritis Cartilage*. 2009;17:1–7.
89. Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. *Ann Rheum Dis*. 2010;69:374–379.
90. Hmamouchi I, Allali F, Tahiri L, et al. Clinically important improvement in the WOMAC and predictor factors for response to

- non-specific non-steroidal anti-inflammatory drugs in osteoarthritic patients: a prospective study. *BMC Res Notes*. 2012;5:58.
91. Chan FK, Abraham NS, Scheiman JM, et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. *Am J Gastroenterol*. 2008;103:2908–2918.
 92. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. *Circulation*. 2011;123:2226–2235.
 93. Underwood M, Ashby D, Cross P, et al. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. *BMJ*. 2008;336:138–142.
 94. Doi T, Akai M, Fujino K, et al. Effect of nonsteroidal anti-inflammatory drug plasters for knee osteoarthritis in Japanese: a randomized controlled trial. *Mod Rheumatol*. 2010;20:24–33.
 95. Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. *Pain*. 2009;143:238–245.
 96. Kosuwon W, Sirichatiwapee W, Wisanuyotin T, et al. Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo. *J Med Assoc Thai*. 2010;93:1188–1195.
 97. Lee YH, Woo JH, Choi SJ, et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. *Rheumatol Int*. 2010;30:357–363.
 98. Fransen M, Agalotiis M, Naim L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. *Ann Rheum Dis*. 2015;74:851–858.
 99. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. *Ann Rheum Dis*. 2010;69:1459–1464.
 100. Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. *Ann Rheum Dis*. 2015;74:547–556.
 101. Maheu E, Cadet C, Marty M, et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. *Ann Rheum Dis*. 2014;73:376–384.
 102. Hirsch G, Kitas G, Klocke R. Intra-articular corticosteroid injection in osteoarthritis of the knee and hip: factors predicting pain relief—a systematic review. *Semin Arthritis Rheum*. 2013;42:451–473.
 103. Miller LE, Block JE. US-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and meta-analysis of randomized, saline-controlled trials. *Clin Med Insights Arthritis Musculoskeletal Disord*. 2013;6:57–63.
 104. Shen X, Gatti R. The safety and efficacy of intra-articular dual molecular weighted hyaluronic acid in the treatment of knee osteoarthritis: the I.d.e.h.a. Study. *Orthop Rev (Pavia)*. 2013;5:e33.
 105. Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. *Ann Rheum Dis*. 2013;72:179–186.
 106. Lafeber FP, van Laar JM. Strontium ranelate: ready for clinical use as disease-modifying osteoarthritis drug? *Ann Rheum Dis*. 2013;72:157–161.
 107. Jones B. Osteoarthritis: evaluating strontium ranelate treatment for knee OA. *Nat Rev Rheumatol*. 2012;8:693.
 108. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. *Pain*. 2009;146:253–260.
 109. Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. *Age Ageing*. 2012;41:646–652.
 110. Abou-Raya A, Abou-Raya S, Khadrawi T, et al. Effect of low-dose oral prednisolone on symptoms and systemic inflammation in older adults with moderate to severe knee osteoarthritis: a randomized placebo-controlled trial. *J Rheumatol*. 2014;41:53–59.
 111. Filardo G, Kon E, Di Martino A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. *BMC Musculoskelet Disord*. 2012;13:229.
 112. Sanchez M, Anitua E, Azofra J, et al. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. *Clin Exp Rheumatol*. 2008;26:910–913.
 113. Sampson S, Reed M, Silvers H, et al. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. *Am J Phys Med Rehabil*. 2010;89:961–969.
 114. Wang-Saegusa A, Cugat R, Ares O, et al. Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. *Arch Orthop Trauma Surg*. 2011;131:311–317.
 115. Napolitano M, Matera S, Bossio M, et al. Autologous platelet gel for tissue regeneration in degenerative disorders of the knee. *Blood Transfus*. 2012;10:72–77.
 116. Spakova T, Rosocha J, Lacko M, et al. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. *Am J Phys Med Rehabil*. 2012;91:411–417.
 117. Dold AP, Zywielski MG, Taylor DW, et al. Platelet-rich plasma in the management of articular cartilage pathology: a systematic review. *Clin J Sport Med*. 2014;24:31–43.
 118. Davis AJ, Smith TO, Hing CB, et al. Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. *PLoS One*. 2013;8:e72714.
 119. Gamero P, Aronstein WS, Cohen SB, et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. *Osteoarthritis Cartilage*. 2008;16:660–666.
 120. Iwamoto J, Takeda T, Sato Y, et al. Effects of risedronate on osteoarthritis of the knee. *Yonsei Med J*. 2010;51:164–170.
 121. Arti HR, Azemi ME. Comparing the effect of glucosamine and glucosamine with alendronate in symptomatic relieve of degenerative knee joint disease: a double-blind randomized clinical trial study. *Jundishapur J Nat Pharm Prod*. 2012;7:87–92.
 122. Laslett LL, Dore DA, Quim SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. *Ann Rheum Dis*. 2012;71:1322–1328.
 123. Bhattacharya I, Saxena R, Gupta V. Efficacy of vitamin E in knee osteoarthritis management of North Indian geriatric population. *Ther Adv Musculoskelet Dis*. 2012;4:11–19.
 124. Jacquet A, Girodet PO, Pariente A, et al. Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial. *Arthritis Res Ther*. 2009;11:R192.
 125. Cao Y, Jones G, Cicuttini F, et al. Vitamin D supplementation in the management of knee osteoarthritis: study protocol for a randomized controlled trial. *Trials*. 2012;13:131.

126. Peregoy J, Wilder FV. The effects of vitamin C supplementation on incident and progressive knee osteoarthritis: a longitudinal study. *Public Health Nutr.* 2011;14:709–715.
127. Wenham CY, Grainger AJ, Hensor EM, et al. Methotrexate for pain relief in knee osteoarthritis: an open-label study. *Rheumatology (Oxford).* 2013;52:888–892.
128. Koh YG, Jo SB, Kwon OR, et al. Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. *Arthroscopy.* 2013;29:748–755.
129. Sloan FA, George LK, Hu L. Longer term effects of total knee arthroplasty from a national longitudinal study. *J Aging Health.* 2013;25:982–997.
130. Bhatia D, Bejarano T, Novo M. Current interventions in the management of knee osteoarthritis. *J Pharm Bioallied Sci.* 2013;5:30–38.
131. Sihvonen R, Paavola M, Malmivaara A, et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. *N Engl J Med.* 2013;369:2515–2224.
132. de Groot IB, Bussmann HJ, Stam HJ, et al. Small increase of actual physical activity 6 months after total hip or knee arthroplasty. *Clin Orthop Relat Res.* 2008;466:2201–2208.
133. Shin CS, Lee JH. Arthroscopic treatment for osteoarthritic knee. *Knee Surg Relat Res.* 2012;24:187–192.
134. Luque R, Rizo B, Urda A, et al. Predictive factors for failure after total knee replacement revision. *Int Orthop.* 2014;38:429–435.
135. Legout L, Senneville E. Periprosthetic joint infections: clinical and bench research. *ScientificWorldJournal.* 2013;2013:549091.
136. Helwig P, Morlock J, Oberst M, et al. Periprosthetic joint infection—effect on quality of life. *Int Orthop.* 2014;38:1077–1081.